Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicriviroc in treatment-experienced HIV (VICTOR-E4)
NCT00474370Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Vicriviroc Arm with Placebo Arm (2 arms). Primary endpoint: Proportion of subjects with undetectable plasma HIV-1 RNA (<50 copies/mL) at 48 weeks. Started May 2007; status: completed.
02
Drugs
vicriviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00474370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00474370.